About us

Eukarÿs develops and produces mRNA-based therapeutics

Eukarÿs is a privately-held biotechnology company which develops and manufactures therapeutic messenger RNA (mRNA) utilizing its high performance high yield cell-free mRNA production platform, based on its novel C3P3® technology, a non-viral expression technology.

Our mission is to develop clinically effective mRNA-based therapeutics and fill unmet medical needs – initially for rare monogenic diseases in the area of hepatology.

The company will soon launch its first gene therapy program to develop a mRNA-based orphan drug to treat Wilson Disease, a genetic disease that affects approximately 1 in 15,000.

Eukarÿs was founded in 2010 and is headquartered in Paris, France. It is the prize-winner and laureate of several contests and is member of biotech clusters:

logo_laureat_ministere_recherche_2009

 

2009 Prize-winner of the French National Contest for Innovative Technologies Companies

 

 

 

logo_laureat_ministere_recherche_2011

 

2011 Prize-winner of the French National Contest for Innovative Technologies Companies

 

 

 

logo_label_entreprise_innovante_pole_competitivite

 

Labelled Innovative Companies by French global competitiveness clusters

 

 

 

logo_Templin_entreprise_2013

 

2013 Laureate of Tremplin Entreprises – Private National Contest for Innovative Technologies Companies in France (French Senate and ESSEC Business School)

 

 

logo_Label_Techinnov_2013

 

2013 Laureate of Techinnov – Event dedicated to innovation in Europe

 

 

 

logo_pole_competitivite_medicen

 

Member of Medicen Paris Region global competitiveness life science cluster

 

 

logo_hepatinov_club_pme

 

Active member of French clinical research cluster DHU Hepatinov (hepatology)

 

 

logo-genopole

 

Member of Genopole, France’s leading biotech- and biotherapy-dedicated science and business park”

 

 

 

 

LOGO_IAR_competitivite_agro_ressources_industrie

 

Member of the French Industry and Agro-resource (IAR) Cluster